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ABSTRACT Lipid mediators play an important role
in reproductive biology, especially, in parturition. En-
hanced biosynthesis of eicosanoids, such as prostaglan-
din E2 (PGE2) and PGF2, precedes the onset of labor
as a result of increased expression of inducible cyclo-
oxygenase 2 (COX-2) in placental tissues. Metabolism
of arachidonic acid results in bioactive lipid mediators
beyond prostaglandins that could significantly influence
myometrial activity. Therefore, an unbiased lipidomic
approach was used to profile the arachidonic acid
metabolome of amniotic fluid. In this study, liquid
chromatography–mass spectrometry was used for the
first time to quantitate these metabolites in human
amniotic fluid by comparing patients at midtrimester, at
term but not in labor, and at term and in spontaneous
labor. In addition to exposing novel aspects of COX
pathway metabolism, this lipidomic study revealed a
dramatic increase in epoxygenase- and lipoxygenase-
pathway-derived lipid mediators in spontaneous labor
with remarkable product selectivity. Despite their rec-
ognition as anti-inflammatory lipid mediators and reg-
ulators of ion channels, little is known about the
epoxygenase pathway in labor. Epoxygenase pathway
metabolites are established regulators of vascular ho-
meostasis in cardiovascular and renal physiology. Their
presence as the dominant lipid mediators in spontane-
ous labor at term portends a yet undiscovered physiolog-
ical function in parturition.—Maddipati, K. R., Romero,
R., Chaiworapongsa, T., Zhou, S.-L., Xu, Z., Tarca, A. L.,
Kusanovic, J. P., Munoz, H., Honn, K. V. Eicosanomic
profiling reveals dominance of the epoxygenase pathway
in human amniotic fluid at term in spontaneous labor.
FASEB J. 28, 4835–4846 (2014). www.fasebj.org
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Prostaglandins (PGs), bioactive lipid mediators of
arachidonic acid metabolism via the cyclooxygenase
(COX) pathway, are known to play an important role in
reproductive physiology (1–6). Increased expression of
the inducible form of COX, COX-2, in human amnion
is responsible for the increased biosynthesis of PGs with
the onset of labor (7). Myometrial contractility at term
is mediated, at least in part, by PGs E2 and F2 (PGE2
and PGF2), and pharmacologic administration of
PGE2 or PG analogues, such as misoprostol, is routinely
used in clinical practice to induce labor (8–10). Immu-
noassay measurements of amniotic fluid concentrations
of PGs (PGE2, PGD2, PGF2, and others) and throm-
boxanes (Txs; TxA2, measured as TxB2) show increases
preceding the onset of labor, as well as an uneven
spatial distribution in the amniotic cavity with the
progression of labor (2, 3, 11). Such spatiotemporal
analyses of PGs and their metabolites significantly con-
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tributed to our understanding of their role in parturi-
tion. Similar immunoassay analyses of amniotic fluid
samples for lipoxygenase (LOX) pathway-derived lipid
mediators revealed an increase in the concentration of
5-hydroxyeicosatetraenoic acid (5-HETE), 12-HETE,
and leukotriene C4 (LTC4) in spontaneous labor at
term. However, relatively little is known about their
roles in parturition (12–14). The COX pathway has
been the primary focus of lipid mediator participation
in parturition, whereas the other 2 major pathways of
arachidonic acid metabolism, LOX and epoxygenase,
are largely unexplored. Moreover, immunoassay-based
measurements, although highly sensitive, are limited by
the availability, selectivity, and specificity of the anti-
bodies to the products of the arachidonic acid metabo-
lome. Antibody cross-reactivity of structurally related
molecules and nonspecific interferences from biologi-
cal samples are potential sources of error in quantifica-
tion and identification by immunoassays, illustrated by
the cross-reactivity of PGE2 and PGE2-ethanolamide to
the PGE2 antibodies commonly used in enzyme and
radio immunoassays (15). The position statement by
the Endocrine Society on the measurement of testoster-
one in clinical samples further emphasizes the need to
reduce reliance on immunoassays (16). Significant tech-
nological advances in mass spectrometry, especially for
lipid identification and quantification, can help allay the
ambiguity presented by immunometric analyses (17).
Also, physicochemical evidence for the presence of bioac-
tive molecules in vivo and at concentrations that are
potentially relevant from a physiological standpoint (suf-
ficient to activate receptor-mediated signaling, for exam-
ple), is essential before any conclusions on their physio-
logical role can be drawn from in vitro experiments (18,
19). Therefore, an unbiased liquid chromatography–mass
spectrometry (LC-MS) analysis of the eicosanoid lipidome
of amniotic fluid was performed to unambiguously iden-
tify and quantify the in vivo lipid mediators derived from
arachidonic acid. We present the eicosanomic profiles of
amniotic fluid from patients at term, with or without
spontaneous labor, and identify, for the first time, the
heretofore unknown participation of the epoxygenase
pathway metabolites in term gestation.
MATERIALS AND METHODS
Study design and population
A retrospective cross-sectional study was conducted by search-
ing the clinical database and Bank of Biological Specimens of
the Detroit Medical Center (Wayne State University) and the
Perinatology Research Branch [Eunice Kennedy Shriver Na-
tional Institute of Child Health and Human Development
(NICHD), National Institutes of Health, U.S. Department of
Health and Human Services]. The LC-MS study included
women with singleton pregnancies who had amniotic fluid
samples obtained by transabdominal amniocentesis in the
following groups: women who underwent amniocentesis for
genetic indications in the midtrimester (MT) of pregnancy
(14–18 wk) and delivered at term (n18); women at term not
in labor (TNL; n10); and women at term in labor (TLB,
n35). Patients who had positive cultures for microorganisms
were excluded. Demographic and clinical characteristics of
these study groups are shown in Table 1.
All women provided written, informed consent before the
collection of biological specimens. The collection and exper-
imental use of the samples were approved by the Human
Investigation Committees of the participating institutions, the
Institutional Review Board of the NICHD, and Wayne State
University.
Clinical definition
Spontaneous labor at term was defined as the presence of
regular uterine contractions with a frequency of 1 every 10
min and cervical changes after 37 wk of gestation.
Sample collection
Amniotic fluid samples were obtained by transabdominal
amniocentesis performed for genetic indications, evaluation
of the microbial status of the amniotic cavity, and assessment
of lung maturity in fetuses approaching term. TLB group
women consisted of those who were admitted for suspected
preterm labor because of uncertain dates and had an amnio-
centesis for the assessment of fetal lung maturity. The criteria
for considering whether these patients were in labor at term
were derived retrospectively, and were spontaneous labor;
delivery within 24 h of amniocentesis; results of amniotic fluid
analysis consistent with fetal lung maturity; birth weight
2500 g; absence of respiratory distress syndrome or other
complications of prematurity; and pediatric physical exami-
nation results consistent with those of a term neonate.
Samples of amniotic fluid were transported to the laboratory
in a sterile, capped syringe and cultured for aerobic and
anaerobic bacteria and genital mycoplasmas. White blood cell
(WBC) count (20), glucose concentration (21), and Gram
stain (22) were also performed shortly after amniotic fluid
collection (20, 21). The results of these tests were used for
clinical management. Amniotic fluid not needed for clinical
assessment was centrifuged at 1300 g for 10 min at 4°C, and
the supernatant was stored at 70°C.
TABLE 1. Clinical and obstetrical characteristics of women in the study groups
Parameter MT TNL TLB
P
MT vs. TNL TNL vs. TLB
n 18 10 35 – –
Maternal age (yr) 36 (34–39) 23 (19–31) 23 (20–29) 0.001 0.1
GA at amniocentesis (wk) 16.1 (16.0–16.7) 39.3 (38.7–40.3) 39 (38–40.2) 0.001 0.1
GA at delivery (wk) 39.0 (38.0–40.0) 39.3 (38.7–40.3) 39 (38–40.2) 0.7 0.1
Birth weight (g) 3444 (3160–3899) 3235 (3050–3635) 3250 (3100–3730) 0.2 0.2
GA, gestational age. Values are expressed as medians with interquartile range in parentheses. P by Mann-Whitney U test.
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Sample preparation for LC-MS analysis
Amniotic fluid samples were extracted to determine fatty
acyl lipidome according to a validated method with minor
modifications (23). Briefly, 200 l of the sample was spiked
with 5 ng each of the internal standards (ISs), 15(S)-HETE-
d8, LTB4-d4, and PGE1-d4 (delivered in 5 l methanol).
The samples were diluted to 1 ml with 15% methanol in
water and purified on C18 solid-phase extraction cartridges
(30 mg sorbent, 1 ml; Strata-X; Phenomenex, Torrance,
CA, USA). The cartridges were preconditioned with 1 ml
methanol followed by 1 ml 15% methanol in water. The
diluted, IS-spiked sample was applied to the cartridge,
washed with 2 ml of 15% methanol and 2 ml hexane, and
dried in a vacuum for 30 s. The cartridge was eluted with
0.5 ml methanol containing 0.1% formic acid directly into
1.5 ml LC-MS autosampler vials. The eluate was dried
under a gentle stream of nitrogen, and the residue was
immediately reconstituted with 25 l methanol. The recon-
stituted sample was stored at 80°C until LC-MS analysis.
At the time of the analysis, the sample was brought to room
temperature, and 25 l of 25 mM aqueous ammonium
acetate was added, mixed thoroughly, and loaded in the
autosampler, maintained at 15°C. A pilot study was con-
ducted for 2 h to assess the stability of the eicosanoids in
the amniotic fluid, according to our published method
(23). There were no discernible changes in the concentra-
tion or chemical integrity of the eicosanoids, similar to our
earlier results (data not shown).
LC-MS methods
HPLC was performed on a C18 column [Luna, C18(2);
2.1150 mm, 3 m; Phenomenex), mounted on the Promi-
nence XR HPLC system (Shimadzu, Kyoto, Japan). The
mobile phase consisted of a gradient between solution A,
methanol-water-acetonitrile (10:85:5 v/v/v), and solution B,
methanol-water-acetonitrile (90:5:5 v/v/v), both containing
0.1% ammonium acetate. The gradient program with respect
to the composition of solution B was as follows: 0–1 min, 50%;
1–8 min, 50–80%; 8–15 min, 80–95%; and 15–17 min, 95%.
The flow rate was 0.2 ml/min. The HPLC column was fully
equilibrated to initial conditions before each sample was
injected. The HPLC eluate was directly introduced to the
electrospray ionization source (TurboV) of the QTrap5500
mass analyzer (AB Sciex, Framingham, MA, USA) in the
negative ion mode with the following settings: curtain gas,
35 psi; GS1, 35 psi; GS2, 65 psi; temperature, 600°C; ion
spray voltage, 1500 V; collision gas, low; declustering
potential, 60 V; and entrance potential, 7 V. The eluate
was monitored by the multiple reaction monitoring (MRM)
method, to detect unique molecular ion– daughter ion
combinations for each of the 60 transitions (to monitor a
total of 69 lipid mediators from arachidonic acid metabo-
lism; see Supplemental Table S1 for details) with 8 ms
dwell time for each transition and 5 ms settling time
between scans. The total cycle time was 1.625 s. Optimized
collisional energies (18 –35 eV) and collision cell exit
potentials (7–10 V) were used for each MRM transition.
The data were collected with Analyst 1.5.2 software (AB
Sciex), and the MRM transition chromatograms were quan-
titated by MultiQuant software (AB Sciex). The IS signals
in each chromatogram were used for normalization, recov-
ery, and relative quantitation of each analyte (see Supple-
mental Table S1 for analyte IS combinations used for
quantitation). Concentration of each detected analyte in
amniotic fluid was calculated by dividing the detected
quantities (in nanograms) with their corresponding molec-
ular masses and reported as nanomolar. Under standard-
ized conditions, the detection limits of most eicosanoids
are 	2 pg on the column, and the limit of quantitation is
5 pg at a signal-noise ratio of 3. Since the sample volume
used was 200 l, this condition translates to an assay
sensitivity of 0.03 nM for an average molecular mass of 330
of the detected eicosanoids.
Statistical analysis
For any detectable lipid analyte in a subject group, a 0 value
observed in any sample was replaced with half the average
detection limit of the LC-MS method used for the eicosanoids
(i.e., 0.015 nM). This method ensures that information from
all samples was used in the statistical analysis and that the fold
change between groups was finite for each analyte. A Wil-
coxon test, which does not rely on any distributional assump-
tions about the data, was used for all pair-wise group compar-
isons. The significance of the P value of the Wilcoxon test is
independent of the choice of the threshold concentration
used to replace the values below the quantitation limits of the
assay.
A parametric alternative to the Wilcoxon test was also
applied by using a t test for analytes with concentrations above
the quantitation limits of the assay in all samples or using
censored regression otherwise. In the presence of a perfect
separation between groups, the maximum-likelihood estima-
tion involved in censored regression could not be applied,
and hence a t test was used instead.
To account for multiple testing, the P values obtained for
all analytes in the 2-group comparison were adjusted to
control the false discovery rate (FDR; ref. 24). A threshold of
10% FDR inferred significance.
All analyses were performed in the R 3.0 statistical lan-
guage and environment, (http://www.r-project.org), with the
censReg R package for the censored regression analysis (25).
RESULTS
Patients and samples
The demographic and clinical characteristics of the
patients (MT, TNL, and TLB groups) are given in
Table 1. By design, the patients in the MT group were
older than those in the TNL group (median 36 vs. 23
yr; P0.001). However, there was no significant differ-
ence in median maternal age between the women in
the TNL and TLB groups (P0.1).
LC-MS analysis of the amniotic fluid fatty acyl
lipidome
Reverse-phase HPLC combined with MRM LC-MS re-
solved nearly all primary products of common polyun-
saturated fatty acids (PUFAs) by the 3 major pathways:
COX, LOX, and epoxygenase, as well as their down-
stream metabolites. A combination of 3 internal stan-
dards (15-HETE-d8, LTB4-d4, and PGE1-d4) that span
the chromatographic polarity range of arachidonic acid
metabolites was used to monitor recovery during ex-
traction and quantify the detected metabolites. This
method examined relative response ratios of the me-
tabolites to the corresponding ISs for quantitation (23).
The identity of each detected metabolite was unambig-
uously confirmed by both the MRM transition and
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comparison of retention time to that of the authentic
standard. The HPLC method also resolves diastereom-
ers [compounds with 1 stereo center; LTB4 and
5(S),12(S)-dihydroxyeicosatetraenoic acid (diHETE),
for example]. However, stereochemistry of the HETEs
could not be ascertained by chiral chromatography due
to the limited availability of the samples. Data for the
analytes with significantly different levels between pa-
tient groups (P0.05 and FDR0.1) are shown in the
figures. Complete data [means
sem, median inter-
quartile range (IQR), fold change, P values, and FDR]
for all detected eicosanoids are included in Supplemen-
tal Table S2.
Analysis of amniotic fluid from women in the 3
patient groups revealed arachidonic acid metabolism,
as reported previously, by the COX and LOX pathways,
in addition to the novel finding of significant epoxyge-
nase pathway activity.
Epoxygenase pathway products
This study revealed, for the first time, the presence of
epoxyeicosatrienoic acids (EpETrEs) in human amni-
otic fluid samples (Fig. 1). The most abundant metab-
olite detected at TLB was 11(12)-EpETrE (median, 191
nM). Two other stable epoxides, 14(15)- and 8(9)-
EpETrEs, were present at lower concentrations (me-
dian, 109 and 39 nM, respectively). All 3 epoxides
showed a 9- to 10-fold higher median concentration at
term (MT vs. TNL or TLB) and a further 2-fold higher
median concentration in the women in labor (TNL vs.
TLB). The fourth potential epoxide from arachidonic
acid, 5(6)-EpETrE, is highly unstable and spontane-
ously decomposes to the corresponding 5,6-dihy-
droxyeicosatrienoic acid (5,6-diHETrE), in aqueous
solutions (23, 26). Although detectable in amniotic
fluid, the 5,6-diHETrE concentration was minimal
(	1%) when compared to the other 3 EpETrEs, indi-
cating low levels of the parent 5(6)-EpETrE (Supple-
mental Table S2). Hydrolysis products (diHETrEs) of
the other 3 stable epoxides accounted for1% of their
corresponding EpETrEs, suggesting little, if any, epox-
ide hydrolase activity in the amniotic cavity (see Fig. 6
and Supplemental Table S2). The -hydroxylase-de-
rived lipid mediator 20-HETE was detected in 80% of
the amniotic fluid samples of the women in the TLB
group (median, 2.7 nM), but not of the women in the
MT group, and in only 50% of those in the TNL group
(median, 0.8 nM).
COX pathway products
The presence of PGs and their metabolites was exam-
ined in the 3 patient groups (Fig. 2). In the amniotic
fluid of women in the TLB group, PGE2 (median, 37
nM), PGA2 (median, 54 nM), and 13,14-dihydro-15-
keto PGE2 (measured as bicyclo-PGE2; median, 144
nM) showed significantly higher median concentra-
tions compared with fluid from the women in the TNL
group. Other PGs detected at term were PGF2 (me-
dian, 16 nM), 13,14-dihydro-15-keto PGF2 (13,14-dh-
15-k-PGF2; mean, 12 nM), and PGJ2 (median, 27 nM).
These latter products were almost exclusively detected
in the TLB group. Interestingly, none of the PGs were
detectable in the MT group samples compared to the
high nanomolar (median, 12–144 nM) concentrations
detected at term. Even at term, few samples from the
TNL group women had measurable concentrations of
PGs, which, when present, were almost exclusively
PGE2 and its downstream inactive metabolites (Fig. 2
and Supplemental Table S2). In contrast, 19-hydroxy-
PGE
2
(19-OH-PGE2), the -hydroxylation metabolite of
PGE2, was detectable in all samples of amniotic fluid at
term and was the second most abundant eicosanoid
(median TLB, 164 nM; TNL, 139 nM) after 11(12)-
EpETrE. This is the first report of 19-OH-PGE2 detec-
tion and quantification in amniotic fluid. Although the
difference between TLB and TNL was not significant
(P0.99), the median concentration of this metabolite
was significantly higher at term than that in the MT
group (MT vs. TNL; P4.5106).
Figure 1. Epoxygenase and -hydroxylase path-
way products of arachidonic acid detected in
amniotic fluid. Each data point represents
nanomolar concentration of the analyte in a
sample above the detection limit for that ana-
lyte (represented by the dashed line). Circles,
MT; squares, TNL; triangles, TLB; X, median
for each analyte and group.
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LOX pathway products
Mediators of the LOX pathway were detected in most of
the samples (Fig. 3). All possible LOX-derived HETEs
were detectable. Concentrations of the different
HETEs were comparable at MT, and their median
concentrations were collectively higher at later gesta-
tional ages, with the exception of 5-HETE. Median
concentration of 5-HETE was significantly higher with
TLB (TLBTNL; P0.015), but the difference was not
significant between the MT and TNL groups (P0.98).
The other HETEs detected for the first time in amni-
otic fluid were 8-, 9-, and 11-HETE. Although the
median concentrations of 8- and 11-HETE were higher
with both gestational age and labor status, 9-HETE
median concentrations changed only with gestational
age, not with labor status. The most abundant LOX
metabolite was 12-HETE (TLB median, 146 nM), and
its concentration was 7- to 10-fold higher than other
HETEs at term. 12-HETE was also the most significantly
changed LOX metabolite with gestational age (22-fold,
TNLMT). However, the median concentration
change was considerably less dramatic with the status of
TLB (1.63-fold; TLBTNL). Surprisingly, the neutro-
Figure 2. COX pathway metabolites detected in amniotic fluid samples. Each data point represents nanomolar concentration
of the analyte in a sample above the detection limit for that analyte (represented by the dashed line). Circles, MT; squares, TNL;
triangles, TLB; X, median for each analyte and group.
Figure 3. LOX pathway products of arachidonic acid detected in amniotic fluid samples. Each data point represents nanomolar
concentration of the analyte in a sample above the detection limit for that analyte (represented by the dashed line). Circles, MT;
squares, TNL; triangles, TLB; X, median for each analyte and group.
4839EICOSANOMIC PROFILE OF HUMAN AMNIOTIC FLUID AT TERM
phil chemotactic lipid mediator LTB4 was detectable in
only 	50% of the samples at TLB and was essentially
absent at MT and at TNL. In addition to the novel
discovery of 8-, 9-, and 11-HETE mentioned above, we
report, for the first time, lipoxin B4 (LXB4) and
5(S),12(S)-diHETE, mediators derived from dual LOX
activities. These lipids were detected in amniotic fluid of
the women in labor at term but were undetectable at MT.
DISCUSSION
The following are the major findings of this unbiased
and comprehensive eicosanomic analysis: human am-
niotic fluid at term contained high concentrations of
arachidonic acid metabolites of the epoxygenase path-
way, which were higher in spontaneous labor; PGE2, at
term, was metabolized substantially to 19-OH-PGE2; an
expanded range of LOX pathway metabolites, such as
8-, 9-, and 11-HETEs, 5(S),12(S)-diHETE, and LXB4,
were detected in the amniotic fluid; and several eico-
sanoids previously detected by immunoassays in the
amniotic fluid were not confirmed by MS.
Immunometric vs. MS analysis of eicosanoids
Arachidonic acid metabolism by the COX, LOX, and
epoxygenase pathways results in the formation of mul-
tiple physiologically active lipid mediators (Fig. 4).
Products of the COX pathway, such as PGE2, PGF2,
PGD2, prostacyclin (PGI2), and TxA2, were shown to
increase in human amniotic fluid preceding the onset
of labor and are known to influence myometrial con-
tractility (2–4, 11, 27, 28). Similar analyses revealed that
the LOX pathway metabolites 5-HETE, 12-HETE, 15-
HETE, LTB4, and LTC4, increased in amniotic fluid in
spontaneous labor at term (12, 13, 29, 30). The re-
ported concentrations of eicosanoids detected and
quantified by immunoassay were highly variable and
differed significantly from the LC-MS-measured con-
centrations in the current study (Table 2). Despite the
variability, the importance of the earlier investigations
cannot be underestimated for revealing the role of
eicosanoids in parturition. However, using immuno-
logic approaches for the identification and quantita-
tion of small molecules in complex biological samples
can lead to misidentification and overestimation due to
antibody cross-reactivity (15). This possibility necessi-
tates confirmation by physicochemical techniques, such
as MS or NMR, before entertaining immunochemical
methods for quantification. For example, PGD2 was
undetectable by LC-MS in the current study. It is well
known that PGD2 nonenzymatically dehydrates to PGJ2
in the presence of proteins (31). PGJ2 was detected in
TLB samples by LC-MS at a higher concentration
(median, 25.9 nM) than previously reported for PGD2
(mean, 5.07
1.4 nM) by immunoassay (11). This
anomaly may be due to PGD2 antibody cross-reactivity
with PGJ2 (32). If the anti-PGD2 antibody used in the
earlier study exhibited similar cross-reactivity as the
currently available commercial antibody (Cayman
Chemical Co., Ann Arbor, MI, USA; cat. no. 512013,
22% antibody cross-reactivity with PGJ2), the immuno-
assay-detected PGD2 from 25.9 nM PGJ2 would be 5.9
nM, similar to that reported by Berryman et al. (11). In
addition, other eicosanoids that have been identified in
human amniotic fluid by immunoassay—for example,
LTC4, 11-PGF2 (an enzymatic reduction product of
PGD2), 6-keto PGF1, and TxB2 (nonenzymatic decom-
position products of PGI2 and TxA2, respectively)—
were not confirmed in this study by LC-MS, despite a
detection limit of 2 pg on the column (see Materials
and Methods for details). Although it was difficult to
ascertain the specific molecules that led to the positive
signals for the reported eicosanoids in the immunoas-
says, interference in immunoassays is not uncommon
and requires positive confirmation by physicochemical
methods (15, 18, 19, 33).
Another inherent limitation of immunoassays is the
detection of a single analyte based on the selectivity of
Figure 4. Schematic representation of the amniotic fluid eicosanoid profile. All eicosanoids significantly increased at term; their
biosynthetic pathways from arachidonic acid (included in the heat map; see Fig. 6) are shown. Eicosanoids that showed
significant differences between TLB and TNL groups are highlighted in bold. Intermediates of the biosynthetic pathways that
were not detected (or were not detectable due to their inherent instability) are shown in square brackets. Where known, the
primary enzymes of arachidonic acid metabolism are given in italics. Dashed arrows represent the metabolic step involving 1
enzyme.
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the antibody. This precludes a practical and compre-
hensive analysis of eicosanoids and their metabolites.
Chemically unstable lipid mediators, such as PGE2 and
PGD2, are nonenzymatically converted to PGA2 and
PGJ2, respectively, in aqueous medium (31). In addi-
tion, PGs undergo rapid enzymatic inactivation by
PG-15-dh and 13,14-reductase, leading to the formation of
13,14-dh-15-k products (Fig. 4). Therefore, the simultane-
ous measurement of the downstream metabolites along
with the primary PGs in amniotic fluid by LC-MS is
important in ascertaining their actual in vivo concentra-
tions and evaluating their roles in parturition.
Metabolite profile reveals extensive metabolism of
PGs in amniotic fluid in labor at term
PGs and their inactive metabolites
The presence of both the primary PGs (PGE2 and
PGF2) and their downstream inactive metabolites
(bicyclo-PGE2 and 13,14-dh-15-k-PGF2, respectively)
suggests either continued biosynthesis of the primary
PGs, even as they are metabolized, or incomplete
metabolism at the time of amniocentesis. In addition to
metabolic products, PGA2 and PGJ2, the nonenzymatic
dehydration products of PGE2 and PGD2, respectively,
were also detected. Therefore, the total concentration
of PGE2 in the amniotic fluid in labor at term is likely
the sum of median concentrations of PGE2 and PGA2 of
121 nM, whereas, that of PGD2 is 26 nM.
Detection of 19-OH-PGE2 in amniotic fluid at term
19-OH PGE2 is the most abundant eicosanoid present
in human semen (34). It is known for its immunosup-
pressive properties and has been postulated to prevent
sensitization of the female to spermatozoa (35–37).
This study is the first to report on the detection of
19-OH-PGE2 in the amniotic fluid (Fig. 2). Although
the concentrations of 19-OH-PGE2 were not signifi-
cantly different between the TNL and TLB groups, the
ratio of PGE2 to 19-OH-PGE2 was significantly lower in
the TNL group (P0.04; Fig. 5). These results suggest
that the metabolism of PGE2 to 19-OH-PGE2 by the
-hydroxylase pathway is reduced in labor at term.
19-OH-PGE2 is a selective agonist of EP2 receptor
subtype of the PGE2 receptors (38). The myometrium
of a pregnant woman expresses a heterogeneous pop-
ulation of prostanoid receptors, including EP2 and EP3
receptor subtypes (39–41). It is noteworthy that EP2
receptors are present mostly in the lower segment of
the myometrium, whereas the EP3 receptors are con-
centrated in the fundus, leading to the postulation that
PGE2 has a dual function from EP3 receptor activation,
resulting in myometrial contractions, and that EP2
receptors are involved in uterine relaxation for fetal
passage (8). Agonists of the EP2 receptor, such as
butaprost, are known to decrease spontaneous uterine
contractions (39). Therefore, metabolism of PGE2 by
-hydroxylase to 19-OH-PGE2 could contribute to uter-
ine quiescence and initiation of labor from an increase
in the ratio of PGE2 to 19-OH-PGE2 (39, 42).
Absence of Tx and PGI2 in amniotic fluid at term
Other major bioactive lipid mediators of the COX
pathway are TxA2 and PGI2 (detectable as their stable,
nonenzymatic degradation products TxB2 and 6-keto-
PGF1, respectively). However, as discussed above, nei-
ther these primary products, nor their downstream
TABLE 2. Comparison of the concentrations of immunoassay-quantified eicosanoids in amniotic fluid reported in the literature with the
LC–MS-quantified data of the current study
Eicosanoid TNL TLB
Current study
TNL TLB
PGE2 5.89 
 1.13 (79); 0.7 (3); 1.85 (5) 8.74 
 1.71 (79); 3.1 (3); 5.31 (5);
13.1 (2)
24.1 36.7
PGF2 4.1 
 2.1 (80); 0.42 
 0.2 (1);
1.58 
 0.14 (79); 0.85 (3); 0.7 (5)
125 
 92 (80); 61.9 
 16.7 (1);
20.2 
 4.6 (79); 5.23 (3); 12.14
(5); 16.6 (2)
ND 15.6
13,14-dihydro-15-keto-PGF2 2.5 
 0.59 (81); 2.5 
 0.23 (79) 17.4 
 6.8 (81); 5.11 
 0.82 (79);
8.59 (2)
ND 11.9
PGD2 2.63 
 0.65 (11) 5.07 
 1.4 (11) ND ND
11-PGF2 0.58 (28) 1.12 (28) ND ND
6-keto-PGF1 (PGI2) 0.46 
 0.02 (27) 1.67 (2) ND ND
TxB2 (TxA2) 0.09 
 0.02 (27) 0.37 (2) ND ND
a
5-HETE 13.8 
 5.3 (14); 6.18 (13) 11.06 (13) 8.2 12.8
12-HETE 35.94 (29) 77 (29) 104.7 146.4
15-HETE 1.4 (29) 13.6 (29) 8.6 22.1
LTB4 0.06 (29) 0.29 (29) 3.4 4.0
LTC4 0.12 (12) 0.19 (12) ND ND
Published data are variably presented as picograms or nanograms per milliliter or nanomolar. All data have been converted and are
presented as nanomolar in the table. Data without standard deviations are median values, with the exception of 11-PGF2, which is an average
of duplicate samples. Numbers in parentheses indicate the source references from which the data were collected. ND, not detected by the LC-MS
method used in the current study or below the detection limit (average detection limit across the panel of eicosanoids was 0.015 nM). aDetected
in only 2 of 35 samples.
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metabolites (e.g., 11-dh-TxB2 and 2,3-dinor-TxB2 from
TxB2 or 6,15-diketo-PGF1 from 6-keto-PGF1) were
detectable in the amniotic fluid samples. Therefore,
neither TxA2 nor PGI2 appears to play a role in
spontaneous labor at term. A recent report on MS
analysis of amniotic fluid showed significant TxB2 and
6-keto-PGF1 concentrations at term (43). However,
different sampling methods used to retrieve the amni-
otic fluid are the likely reason for the differences
between the two LC-MS-based analyses. Amniotic fluid
used in the study by Menon et al. (43) was retrieved by
transvaginal amniotomy from the lower compartment
(forebag) compared to the transabdominal amniocen-
tesis used to retrieve the sample from the superior
amniotic cavity in our current study. Earlier radioim-
munoassay quantitation clearly demonstrated signifi-
cantly higher concentrations of all eicosanoids in the
forebag than in the superior amniotic cavity (2).
12-Hydroxyheptadecatrienoic acid (12-HHTrE) is
another nonenzymatic degradation product of both
TxA2 and PGH2. 12-HHTrE was detectable in 7 of the
35 amniotic fluid samples from the TLB group but
absent in all other samples. Given that there was no
detectable TxB2 in these samples (except in 2 of 35
TLB samples), the origin of 12-HHTrE in the detected
samples was most likely PGH2, which is also the precur-
sor of PGE2 and -F2 (Fig. 4).
LOX metabolites
COX- and LOX-derived HETEs
Metabolism of arachidonic acid by LOXs results in the
formation of hydroperoxides, which are further re-
duced to hydroxy fatty acids by endogenous peroxi-
dases, such as glutathione peroxidases (Fig. 4). Con-
centrations of hydroxy fatty acids derived from
arachidonic acid by the 5-LOX (5-HETE and LTB4),
12-LOX (12-HETE), and 15-LOX (15-HETE) pathways,
in addition to 8-HETE and 11-HETE, were significantly
higher in the TLB group (Fig. 3). COX-2 is known to
catalyze a LOX-type reaction to produce 11-HETE as a
secondary metabolite (44). Considering that COX-2
expression is higher in labor at term, high levels of
11-HETE observed in the TLB group (Fig. 3) may also
reflect COX-2 activity, in addition to its role in elevated
PG biosynthesis. On the other hand, the origin of
8-HETE, which is also significantly higher in TLB, is
uncertain. 8-LOX was characterized in murine keratinocytes
and is considered an orthologue of human 15-LOX-2
(45–47). However, 15-LOX-2 is not known to produce
8-HETE, and no human equivalent of murine 8-LOX
has been identified to date.
Dual LOX products 5(S),12(S)-diHETE and LXB4
Despite their identification in amniotic fluid in earlier
studies, biological activities of HETEs are relatively
uncharacterized in reproductive biology. 5-HETE, but
not 12-HETE or LTB4, has been shown to induce
contractility in vitro in myometrial strips collected from
women not in labor and undergoing cesarean section
(30). The most abundant of the LOX-derived lipid
mediators, 12-HETE, is known to induce cell survival,
migration, and angiogenesis in cancer (48). In the
context of spontaneous labor at term, it is possible that
HETEs serve as chemoattractants to circulating neutro-
phils, or they may activate resident macrophages to
mitigate potential infection during parturition. It is also
possible that the interaction between 5- and 12-LOXs
serve a homeostatic function, to dampen the effects of
inflammatory mediators, such as PGE2, LTB4, and
cytokines. The presence of the dual LOX product,
5(S),12(S)-diHETE (Fig. 6 and Supplemental Table
S2), in spontaneous labor at term suggests the possible
interaction of 5- and 12-LOXs in transcellular biosyn-
thesis (49–51). For example, 12-HETE produced by the
amnion may be metabolized further by infiltrating
neutrophils during term labor to generate the dual
LOX metabolite (52, 53). The role of this dual LOX
product in parturition is not known. However,
5(S),12(S)-diHETE is known to be a partial agonist,
desensitizes LTB4 receptors in leukocytes, and may
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Figure 5. Scatterplot of calculated ratios of the concentrations
of PGE2 to 19-OH PGE2 for each sample at term. Each data
point represents nanomolar concentration of the analyte in a
sample above the detection limit for that analyte. Squares,
TNL; triangles, TLB; X, median for each analyte and group.
P was calculated using a 2-independent-sample Wilcoxon
rank sum test.
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contribute to homeostasis after labor-induced stress
(54). To that end, the LOX pathway (primarily 5- and
12-LOXs) is known to play an important role in damp-
ening and resolving inflammation via the biosynthesis
of LXs from arachidonic acid and resolvins from -3
PUFAs (55, 56). Although the concentration difference
was not statistically significant between the TLB and
TNL groups, we report, for the first time, the detection
of LXB4 in term amniotic fluid samples. This mediator
of resolution was undetectable in MT samples (Fig. 6
and Supplemental Table S2). Thus, the significant
increase in LOX pathway products in spontaneous
labor at term warrants further studies to evaluate their
role in the context of parturition.
Dominance of the epoxygenase pathway metabolites
in amniotic fluid at term
Selective product profile of EpETrEs
By far, the most abundant bioactive lipid mediators of
arachidonic acid, detected for the first time in amniotic
fluid, are the epoxygenase pathway metabolites. PUFA
epoxygenases are not particularly known for their re-
giospecificity of epoxidation (57). Although a specific
isozyme may preferentially catalyze the formation of one
regioisomer, it is not at the exclusion of other isomers. For
example, the epoxygenase CYP2C8 catalyzes arachidonic
acid epoxidation to produce 14(15)-EpETrE and 11(12)-
EpETrE at a ratio of 48:52, but does not generate other
epoxides (Fig. 4 and ref. 58). On the other hand, the
isozyme CYP2B12 metabolizes arachidonic acid almost
exclusively to 11(12)-EpETrE (59).
The 3 stable epoxides of arachidonic acid, 11(12)-
EpETrE, 14(15)-EpETrE, and 8(9)-EpETrE, were de-
tected in amniotic fluid at a ratio of 60:30:10, respec-
tively, with selectivity for 11(12)-epoxygenation (Fig.
1). Patel et al. (60) have reported exclusive formation
of 14(15)-EpETrE in in vitro incubations of arachi-
donic acid with human placental membrane ex-
plants. However, poor resolution of the HPLC
method used and the nonselective nature of UV
detection bring the identity of the detected com-
pound into question. If the structural assignment of
the product from in vitro experiments was indeed
correct, this study underscores further the impor-
tance of analyzing in vivo metabolites to ascertain the
physiological relevance of results from in vitro exper-
iments.
Little evidence for epoxide hydrolysis in amniotic fluid
With the exception of 5(6)-EpETrE, all other epoxides
are remarkably stable in aqueous medium (23). Even if
all the 5,6-diHETrE (the nonenzymatic hydrolysis prod-
uct of 5(6)-EpETrE) detected in this study was attrib-
uted to its parent epoxide, the median concentration in
spontaneous labor at term was only 1.97 nM (Supple-
mental Table S2) compared to 191 nM for 11(12)-
EpETrE. EpETrEs are biologically inactivated by
soluble epoxide hydrolase to their corresponding di-
HETrEs (61, 62). However, the levels of dihydroxy fatty
acids derived from the 3 stable epoxides were either
undetectable or extremely low in amniotic fluid. The
only hydrolysis product detected was 14,15-diHETrE
[that of 14(15)-EpETrE], and the ratio of median
epoxide/diHETrE was 101 for the TLB group, suggest-
ing little, if any, epoxide hydrolase activity in the
amniotic cavity (Supplemental Table S2).
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Figure 6. Heat map representation of analyte concentration. In this representation, only analytes that change significantly
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Potential physiological role for EpETrEs in parturition
Outside of renal and cardiovascular physiology, rela-
tively little is known about the biological activity of
these epoxides. Circulating EpETrEs have been de-
tected in pregnancy, with a further increase in women
with preeclampsia (63–66). Because of their role in
regulating vascular tone and blood pressure, increased
biosynthesis of specific isomers of the epoxides [e.g.,
5(6)-EpETrE with vasoconstrictive properties] are pro-
posed to be involved in pregnancy-induced hyperten-
sion (65, 66). However, other studies suggest that an
increase in renal biosynthesis of 11(12)-EpETrE is
associated with preeclampsia (63). The EpETrE profile
of human amniotic fluid in this study shows that
11(12)-EpETrE is the major isomer associated with
spontaneous labor. Thus, it is likely that different
isomers of EpETrEs have distinct roles in human par-
turition.
Fatty acid epoxides are generally regarded as anti-
inflammatory and participate in the restoration of
tissue homeostasis (62, 67). For example, all EpETrEs
induce relaxation of vascular smooth muscle cells, with
11(12)-EpETrE being the most effective, via the activa-
tion of BKca channels and TRPV4 (57, 68–70). It is of
interest to note that 11(12)-EpETrE is also known to be
anti-inflammatory by virtue of its inhibition of NF-B
activation, as well as fibrinolytic activity (71). However,
14(15)-EpETrE was shown to induce uterine contrac-
tions in vitro at 1011 M levels, compared to 107 M of
other EpETrEs (72). The -hydroxylase product of
arachidonic acid, 20-HETE, identified for the first time
in amniotic fluid, is also known for its vasoconstrictor
activity both by blocking the BKca channels and by
activating L-type Ca2 channels (73). It is also known to
induce myometrial contractility in human tissues in
vitro (74).
Expression and catalytic properties of cytochromes
P450 that catalyze PUFA epoxidation are tissue and
species specific (61, 75). The CYP2C and CYP2J family
of enzymes are known epoxygenases, whereas the
CYP4A and CYP4F families are considered monoxyge-
nases that catalyze -hydroxylation of PUFAs. However,
relatively little is known about the expression of these
enzymes in placental membranes. Pearson et al. (74)
have documented that CYP2J2 and CYP2C9 are the
most predominant epoxygenases expressed in myome-
trium of the women in labor, along with the -hydrox-
ylase CYP4A11. CYP2J2 is known to produce both
11(12)- and 14(15)-EpETrEs in heart, but appears
predominantly to generate 5(6)-EpETrE in myome-
trium (71, 76). On the other hand, CYP2B12, an
enzyme exclusively expressed in a subset of differenti-
ated keratinocytes known as sebocytes, produces mostly
11(12)-EpETrE [with 20% of 8(9)-EpETrE], with ara-
chidonic acid as the preferred substrate (59). Indeed,
the product ratio of 11(12)-EpETrE to 8(9)-EpETrE in
amniotic fluid in spontaneous labor at term is 80:20
(Fig. 3 and Supplemental Table S2). It is noteworthy
that expression of this enzyme coincides with the
morphological appearance of sebaceous glands in the
neonatal rat. An intriguing possibility is that the origin
of 11(12)-EpETrE and 8(9)-EpETrE observed in this
study is fetal skin and that 14(15)-EpETrE, the second
most abundant epoxygenase product, originates from
fetal kidney (60, 63). Kidney is the major source of
cytochrome P450-dependent arachidonate epoxyge-
nases, and the biosynthesis of EpETrEs in renal tissues
has been extensively characterized (57, 77). It is known
that most of the amniotic fluid at term is fetal urine,
and lipid mediators present in fetal urine are known to
influence the biosynthesis of PGs, potentially regulating
the initiation of labor at term (78). Therefore, EpETrEs
from fetal skin and kidney could differentially influ-
ence myometrial contractility and, hence, labor.
In summary, this lipidomic analysis of amniotic fluid
revealed a wide array of bioactive lipid mediators
derived from arachidonic acid, representing the 3
major pathways of its metabolism. A significant number
of the lipid mediators identified in this study have
hitherto been unrecognized in human amniotic fluid.
Unexpectedly, the current study demonstrated the
predominance of anti-inflammatory lipids in spontane-
ous labor at term. Parturition, in the prevailing view, is
a localized inflammatory process mediated in part by
proinflammatory lipids. This study demonstrated the
coexistence of both pro- and anti-inflammatory lipid
mediators in amniotic fluid at term, suggesting a para-
digm shift in our understanding of the role of lipids in
parturition. Further exploration of PUFA metabolic
pathways beyond COX, especially the epoxygenase
pathway, with an assessment of the biological activities
of the metabolites identified in this study, as well as
their regulation in the context of spontaneous labor
most certainly will contribute to our understanding of
their role in parturition.
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